NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.
Dean F. Bajorin
Research Funding - Dendreon
Other Remuneration - Dendreon
Padmanee Sharma
Employment or Leadership Position - SITC (U)
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; Helsinn Therapeutics; Jounce Therapeutics; MedImmune
Stock Ownership - Jounce Therapeutics
Research Funding - Bristol-Myers Squibb
Leonard G. Gomella
Consultant or Advisory Role - Astellas Pharma; Bayer; Dendreon; Janssen
Honoraria - Astellas Pharma; Bayer; Dendreon; Janssen
Research Funding - Astellas Pharma; Dendreon; Janssen
Elizabeth R. Plimack
Consultant or Advisory Role - Dendreon
Research Funding - Dendreon
Peter H. O'Donnell
Honoraria - Dendreon
Jean H. Hoffman-Censits
No relevant relationships to disclose
Thomas W. Flaig
Honoraria - Sanofi
Research Funding - Dendreon; Sanofi ; Veridex
Other Remuneration - Aurora Oncology
David I. Quinn
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
Robert Brownell Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Michael Locker
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Nadeem A. Sheikh
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Todd DeVries
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
Seth P. Lerner
No relevant relationships to disclose